Senolytics associated with changes in bone resorption markers in elderly women over 20 weeks
This phase 2 RCT tested whether senolytic drugs reduce senescent cells and alter bone metabolism markers in elderly women over 20 weeks. The study was open-label and single-center. The abstract states the objective but does not report the findings, sample size, effect sizes, or specific outcomes achieved.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 22, 2024 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 5 months
- Population
- Elderly women
- Primary outcome
- Reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers
- Effect size
- —
- Significance
- Not reported
- Journal
- Not clearly reported; author named as Sundeep Khosla, M.D.
- Published
- Jul 22, 2024
Sources
Primary source
- Sundeep Khosla, M.D. ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.